FDA makes oral lead-in optional for long-acting injectable HIV regimen

The FDA has approved a label update for Cabenuva that makes the oral lead-in period for the long-acting injectable HIV regimen optional, ViiV Healthcare announced Thursday.
Cabenuva, which includes shots of cabotegravir (ViiV Healthcare) and rilpivirine (Janssen Pharmaceuticals) was first approved in January 2021 and is now available to be taken as few as six time per year by virologically suppressed adults on a stable regimen with no history of prior treatment failure or resistance to either drug.
The FDA’s approval of the label update means it is now optional whether patients take oral

The FDA has approved a label update for Cabenuva that makes the oral lead-in period for the long-acting injectable HIV regimen optional, ViiV Healthcare announced Thursday.
Cabenuva, which includes shots of cabotegravir (ViiV Healthcare) and rilpivirine (Janssen Pharmaceuticals) was first approved in January 2021 and is now available to be taken as few as six time per year by virologically suppressed adults on a stable regimen with no history of prior treatment failure or resistance to either drug.
The FDA’s approval of the label update means it is now optional whether patients take oral